A Review on Tau Targeting Biomimetics Nano Formulations: Novel Approach for Targeting Alzheimer's Diseases

Q3 Psychology
Aditya Singh, Shubhra Maheshwari, Jagat Pal Yadav, Aditya Prakash Varshney, Sudarshan Singh, Bhupendra G. Prajapati
{"title":"A Review on Tau Targeting Biomimetics Nano Formulations: Novel\nApproach for Targeting Alzheimer's Diseases","authors":"Aditya Singh, Shubhra Maheshwari, Jagat Pal Yadav, Aditya Prakash Varshney, Sudarshan Singh, Bhupendra G. Prajapati","doi":"10.2174/0118715249289120240321065936","DOIUrl":null,"url":null,"abstract":"\n\nCentral nervous system disorders are prevalent, profoundly debilitating, and poorly\nmanaged. Developing innovative treatments for these conditions, including Alzheimer's disease,\ncould significantly improve patients' quality of life and reduce the future economic burden on\nhealthcare systems. However, groundbreaking drugs for central nervous system disorders have\nbeen scarce in recent years, highlighting the pressing need for advancements in this field. One significant\nchallenge in the realm of nanotherapeutics is ensuring the precise delivery of drugs to their\nintended targets due to the complex nature of Alzheimer's disease. Although numerous therapeutic\napproaches for Alzheimer's have been explored, most drug candidates targeting amyloid-β have\nfailed in clinical trials. Recent research has revealed that tau pathology can occur independently of\namyloid-β and is closely correlated with the clinical progression of Alzheimer's symptoms. This\ndiscovery suggests that tau could be a promising therapeutic target. One viable approach to managing\ncentral nervous system disorders is the administration of nanoparticles to neurons, intending to\ninhibit tau aggregation by directly targeting p-tau. In Alzheimer's disease, beta-amyloid plaques\nand neurofibrillary tau tangles hinder neuron transmission and function. The disease also triggers\npersistent inflammation, compromises the blood-brain barrier, leads to brain shrinkage, and causes\nneuronal loss. While current medications primarily manage symptoms and slow cognitive decline,\nthere is no cure for Alzheimer's.\n","PeriodicalId":9799,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central nervous system agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715249289120240321065936","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Psychology","Score":null,"Total":0}
引用次数: 0

Abstract

Central nervous system disorders are prevalent, profoundly debilitating, and poorly managed. Developing innovative treatments for these conditions, including Alzheimer's disease, could significantly improve patients' quality of life and reduce the future economic burden on healthcare systems. However, groundbreaking drugs for central nervous system disorders have been scarce in recent years, highlighting the pressing need for advancements in this field. One significant challenge in the realm of nanotherapeutics is ensuring the precise delivery of drugs to their intended targets due to the complex nature of Alzheimer's disease. Although numerous therapeutic approaches for Alzheimer's have been explored, most drug candidates targeting amyloid-β have failed in clinical trials. Recent research has revealed that tau pathology can occur independently of amyloid-β and is closely correlated with the clinical progression of Alzheimer's symptoms. This discovery suggests that tau could be a promising therapeutic target. One viable approach to managing central nervous system disorders is the administration of nanoparticles to neurons, intending to inhibit tau aggregation by directly targeting p-tau. In Alzheimer's disease, beta-amyloid plaques and neurofibrillary tau tangles hinder neuron transmission and function. The disease also triggers persistent inflammation, compromises the blood-brain barrier, leads to brain shrinkage, and causes neuronal loss. While current medications primarily manage symptoms and slow cognitive decline, there is no cure for Alzheimer's.
Tau 靶向生物仿生纳米制剂综述:靶向阿尔茨海默病的新方法
中枢神经系统疾病发病率高,严重影响患者的生活,而且治疗效果不佳。开发治疗这些疾病(包括阿尔茨海默病)的创新疗法可以显著改善患者的生活质量,减轻医疗系统未来的经济负担。然而,近年来治疗中枢神经系统疾病的突破性药物非常稀缺,这凸显了这一领域对进步的迫切需求。纳米治疗领域的一个重大挑战是,由于阿尔茨海默病的复杂性,如何确保将药物精确地输送到目标靶点。虽然已经探索了许多治疗阿尔茨海默病的方法,但大多数针对淀粉样蛋白-β的候选药物在临床试验中都失败了。最近的研究发现,tau 病理学可以独立于淀粉样蛋白-β而发生,并且与阿尔茨海默病症状的临床进展密切相关。这一发现表明,tau 可能是一个很有前景的治疗靶点。治疗中枢神经系统疾病的一种可行方法是向神经元施用纳米颗粒,通过直接靶向 p-tau 来抑制 tau 的聚集。在阿尔茨海默病中,β-淀粉样蛋白斑块和神经纤维tau缠结阻碍了神经元的传导和功能。这种疾病还会引发持续性炎症,损害血脑屏障,导致脑萎缩,并造成神经元丢失。虽然目前的药物主要是控制症状和减缓认知能力的衰退,但阿尔茨海默氏症还无法治愈。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Central nervous system agents in medicinal chemistry
Central nervous system agents in medicinal chemistry Psychology-Neuropsychology and Physiological Psychology
CiteScore
2.10
自引率
0.00%
发文量
21
期刊介绍: Central Nervous System Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new central nervous system agents. Containing a series of timely in-depth reviews written by leaders in the field covering a range of current topics, Central Nervous System Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信